Modesto XR 6 Tablet contains Paliperidone 6 mgin an extended-release formulation. 
It is manufactured by Incepta Pharmaceuticals Ltd.  

Indications: Modesto XR (Paliperidone) is indicated for:

• Schizophrenia, including acute treatment and recurrence prevention in adults and adolescents (12 years and older).  
• Schizoaffective disorderas monotherapy and in combination with antidepressants or mood stabilizers in adults.  

Pharmacology: Paliperidone is a psychotropic agent belonging to the benzisoxazole derivatives chemical class. It is the major active metabolite of Risperidone.Paliperidone acts as a centrally active dopamine Type 2 (D₂) antagonist and has predominant serotonin Type 2 (5-HT₂A) antagonist activity.It also acts as an antagonist at α₁ and α₂ adrenergic receptors and H₁ histaminergic receptors.  

Dosage and Administration:

• Adults: The initial dose for both schizophrenia and schizoaffective disorder is usually 6 mg once dailyin the morning.The recommended dose range is 3-12 mg once daily, with a maximum dose of 12 mg/day. Dosage adjustments are made based on individual response and tolerability.   
• Adolescents (12 years and older) for Schizophrenia:
  • Weight < 51 kg: Initial dose is 3 mg once daily, with a recommended range of 3-6 mg/day and a maximum of 6 mg/day.
  • Weight ≥ 51 kg: Initial dose is 3 mg once daily, with a recommended range of 3-12 mg/day and a maximum of 12 mg/day.
• Modesto XR tablets should be swallowed whole with liquid and can be taken with or without food. They should not be chewed, divided, or crushed.

Side Effects: The most common adverse reactions associated with Modesto XR (Paliperidone) include:

• Tachycardia (fast heart rate)
• Akathisia (restlessness and an urge to move)
• Somnolence (drowsiness)
• Tremor
• Dystonia (muscle spasms)
• Cogwheel rigidity (stiffness with jerky movements)
• Anxiety
• Weight increase
• Dyspepsia (indigestion)
• Constipation
• Nasopharyngitis (common cold)  

Precautions: Caution should be exercised when Modesto XR is prescribed in patients with:

• Cardiovascular diseases
• QT prolongation  
• Neuroleptic malignant syndrome (NMS)  
• Tardive dyskinesia (involuntary movements)
• Hyperglycemia (high blood sugar)  
• Dyslipidemia (abnormal lipid levels)
• Obesity  
• Hyperprolactinemia (high prolactin levels)
• Leukopenia, Neutropenia, Agranulocytosis (low white blood cell counts)  
• Seizures
• Potential for Cognitive & Motor Impairment

Drug Interactions:

• Modesto XR should be used with caution with other centrally acting drugs and alcohol.  
• It may antagonize the effect of Levodopa and other dopamine agonists.
• Additive effects on orthostatic hypotension may occur with other drugs that lower blood pressure.
• Strong CYP3A4/P-glycoprotein (P-gp) inducers (e.g., carbamazepine) may decrease paliperidone levels, requiring a dose increase of Modesto XR.Conversely, discontinuing the inducer may require a dose decrease.  
• Co-administration with divalproex sodium can increase paliperidone levels. Dose adjustment of Modesto XR may be necessary.   

Pregnancy and Lactation:

• Pregnancy Category C: Paliperidone should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.
• Paliperidone is excreted in human breast milk. The benefits of breastfeeding should be weighed against the potential risks to the infant.   

Storage: Store in a cool and dry place, away from light. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.